Phase 1 Study of Mesenchymal Stromal Cells, Umbilical Cord Lining Stem Cells (ULSC), in Patients With Polymyositis (PM) and Dermatomyositis (DM)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Umbilical cord derived mesenchymal stem cell therapy-RESTEM (Primary) ; Hydrocortisone
Indications Dermatomyositis; Polymyositis
Focus Adverse reactions

25 Nov 2024 New Source identified and integrated (ClinicalTrials.gov: US National Institutes of Health;NCT04723303)
25 Nov 2024 New trial record
18 Nov 2024 According to a RESTEM Media Release, the company presented data from its Phase 1 trial in an oral presentation at the American College of Rheumatology (ACR) annual meeting, ACR Convergence 2024, held November 14-19, 2024, in Washington, DC.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com